Regencell Bioscience Aktie - RGC

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

28,76

Gebot

28,70

Fragen

29,24

Volumen

15.519

28,625 Tagesbereich 29,3125

3,00 52-Wochen-Bereich 69,00

Marktkapitalisierung

374,25M

Handelsende

29,42

Handelsbeginn

28,83

Letzte Trade

28.71

Letzter Handelszeitpunkt

Finanzvolumen

US$ 449.312

VWAP

28,9524

Durchschnittliches Volumen (3 Mio.)

706.513

Ausgegebene Aktien

13.012.866

Dividendenrendite

Kurs-Gewinn-Verhältnis

-86,90

Gewinn pro Aktie (EPS)

-0,33

Erlöse

Nettogewinn

-4,3M

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration. Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.

Sektor

Medicinal Chems,botanicl Pds

Branche

Medicinal Chems,botanicl Pds

Website

www.regencellbioscience.com

Hauptsitz

Hong Kong, Hkg

Gegründet

Regencell Bioscience Holdings Ltd is listed in the Medicinal Chems,botanicl Pds sector of the NASDAQ with ticker RGC. The last closing price for Regencell Bioscience was US$29,42. Over the last year, Regencell Bioscience shares have traded in a share price range of US$ 3,00 to US$ 69,00.

Regencell Bioscience currently has 13.012.866 shares in issue. The market capitalisation of Regencell Bioscience is US$382,84 million. Regencell Bioscience has a price to earnings ratio (PE ratio) of -86.90.

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial

- The Sik-Kee Au TCM Brain Theory® Assessment for ADHD and ASD (“SKATBT-A3”), which measures the effectiveness of the treatment on the patient’s...

Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period

Regencell Bioscience Holdings Limited (NASDAQ: RGC): Results of EARTH efficacy trial EARTH Efficacy Trials Period of trial 30 January 2022...

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focusing on the research...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.36	-1.23626373626	29.12	31.52	26.723	18744	29.33930339	CS
4	-5.23	-15.3868784937	33.99	41.16	21.0001	94240	30.22111256	CS
12	24.91	647.012987013	3.85	69	3.526	706513	19.49671854	CS
26	24.17	526.579520697	4.59	69	3.526	387340	17.71925823	CS
52	23.41	437.570093458	5.35	69	3	244499	16.23597544	CS
156	6.24	27.7087033748	22.52	69	3	83203	16.49328015	CS
260	16.76	139.666666667	12	69	3	124643	23.70836414	CS

RGC - Frequently Asked Questions (FAQ)

What is the current Regencell Bioscience share price?

The current share price of Regencell Bioscience is US$ 28,76

How many Regencell Bioscience shares are in issue?

Regencell Bioscience has 13.012.866 shares in issue

What is the market cap of Regencell Bioscience?

The market capitalisation of Regencell Bioscience is USD 382,84M

What is the 1 year trading range for Regencell Bioscience share price?

Regencell Bioscience has traded in the range of US$ 3,00 to US$ 69,00 during the past year

What is the PE ratio of Regencell Bioscience?

The price to earnings ratio of Regencell Bioscience is -86,9

What is the reporting currency for Regencell Bioscience?

Regencell Bioscience reports financial results in USD

What is the latest annual profit for Regencell Bioscience?

The latest annual profit of Regencell Bioscience is USD -4,3M

What is the registered address of Regencell Bioscience?

The registered address for Regencell Bioscience is 11/F FIRST COMMERCIAL BUILDING, 33-35 LEIGHTON ROAD, HONG KONG, 999077

What is the Regencell Bioscience website address?

The website address for Regencell Bioscience is www.regencellbioscience.com

Which industry sector does Regencell Bioscience operate in?

Regencell Bioscience operates in the MEDICINAL CHEMS,BOTANICL PDS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
WWWW International Inc	US$ 0,395 (167,62%)	223,58M
OMEXOdyssey Marine Exploration Inc	US$ 1,4979 (75,79%)	285,65M
RTCBaijiayun Group Ltd	US$ 0,3244 (74,88%)	263,23M
GREEGreenidge Generation Holdings Inc	US$ 1,3197 (53,92%)	5,84M
SXTCChina SXT Pharmaceuticals Inc	US$ 2,28 (44,30%)	38,04M
CGTLCreative Global Technology Holdings Ltd	US$ 1,5197 (-75,09%)	3,88M
TOIIWOncology Institute Inc	US$ 0,1015 (-40,22%)	156,14k
COEPCoeptis Therapeutics Holdings Inc	US$ 7,70 (-38,25%)	716,99k
INTSIntesity Therapeutics Inc	US$ 0,56 (-37,78%)	3,21M
SMMTSummit Therapeutics Inc	US$ 23,47 (-36,05%)	24,67M
GNLNGreenlane Holdings Inc	US$ 0,012699 (-15,34%)	355,22M
AGMHAGM Group Holdings Inc	US$ 0,0477 (22,31%)	340,91M
OMEXOdyssey Marine Exploration Inc	US$ 1,4979 (75,79%)	285,65M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 10,455 (19,62%)	266,95M
RTCBaijiayun Group Ltd	US$ 0,3244 (74,88%)	263,23M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Regencell Bioscience Holdings Ltd (RGC)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Regencell Bioscience Holdings Ltd

RGC Neueste Nachrichten

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial

Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RGC - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Regencell Bioscience Holdings Ltd (RGC) Börsenkurse

Regencell Bioscience Holdings Ltd (RGC)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Regencell Bioscience Holdings Ltd

RGC Neueste Nachrichten

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial

Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RGC - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich für ein Konto unter ADVFN

Werbung entfernen